Clinical trial Recruiting at 1 site Interventional Ages 18 to 89

Low-dose whole-body angiography for imaging after stroke or TIA

Official title: The Impact of Performing a Low-dose, Whole-body Angiography as the First Element of an Imaging Assessment Following Stroke or Transient Ischemic Attack in Comparison With Usual Care: a Randomized, Controlled, Open Trial

Run by Centre Hospitalier Universitaire de Nīmes · NCT02662751 · Data updated 2026-11-12

This study is testing whether using a low-dose whole-body angiography can help people who have had a stroke or TIA get diagnosed faster and more accurately compared to standard imaging methods.

More Stroke trials

Quick facts

Study typeInterventional
Ages18 Years to 89 Years
SexAll
Enrollment260 (estimated)
SponsorCentre Hospitalier Universitaire de Nīmes
Academic / other
Locations2 sites (Montpellier and 1 other locations)
StatusRecruiting
StartedOctober 21, 2019
Main results expectedJune 12, 2026
Study endsJune 12, 2026
Registry record updatedMarch 10, 2025
Trial IDNCT02662751 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are patients who have had a stroke or TIA within the past 10 days and meet specific diagnostic criteria.

Probably not a fit

Patients who are currently participating in other biomedical research studies or those with certain medical conditions may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to compare two imaging strategies for patients who have experienced a stroke or transient ischemic attack (TIA). One strategy follows the usual imaging protocols at participating centers, while the other begins with a low-dose whole-body angiography. The study will evaluate the number of clinically significant lesions detected, time to diagnosis, hospitalization duration, and overall diagnostic efficiency. Additionally, it will assess the impact on quality of life and the incidence of new cardiovascular events over a follow-up period of 36 months.

Why it matters

Potential benefit: If successful, this approach could lead to faster and more accurate diagnosis and treatment for stroke and TIA patients.

How similar studies have gone: While this approach is innovative, similar studies have shown promise in improving diagnostic efficiency in stroke management.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* The patient was informed about the implementation of the study, its objectives, constraints and patient rights
* The patient has given free and informed consent and signed the consent
* Patient affiliated with or beneficiary of a health insurance plan
* Patient available for 36 months of follow-up
* The patient has had a stroke (within the past 10 days, diagnosis confirmed by MRI with a diffusion sequence) or transient ischemic attack (within the past 10 days, ABCD2 score greater than 3) without haemorrhage

Exclusion Criteria:

* The patient is currently participating in or has participated in another biomedical research study within the past three months or is currently in an exclusion period determined by a previous study.
* Patient under guardianship or judicial protection
* Refusal to sign the consent
* Inability to correctly inform the patient or his/her trusted person about the study
* The patient is pregnant, parturient, or breastfeeding
* The patient has a contraindication for a treatment used in this study
* Known allergy to contrast medium or severe allergy to iodine
* Known active malignancy or history of cancer treatment
* The patient has already undergone a full body scanner in the previous three months
* Renal failure with creatinine clearance below 60 ml / min
* Monoclonal immunoglobulin
* History of severe symptomatic cardiovascular event (myocardial infarction, aortic dissection, mesenteric ischemia, renal ischemia)
* Emergency situations that hamper the planned course of the study

Where it's running

  • CHRU de Montpellier - Hôpital Gui de Chauliac
    Montpellier, France
    Recruiting
  • CHRU de Nîmes - Hôpital Universitaire Carémeau
    Nîmes, France
    Not yet recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.